GlassScriptPhysician profile
Richard A Roh
NPI 1013974484
$3,164.77
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $444 · 2021: $1,029 · 2022: $854 · 2023: $13.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.85 | 2019-2022 | |
| Avion Pharmaceuticals | $299.80 | 2020-2022 | |
| Therapeuticsmd, INC. | $272.71 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $226.98 | 2020-2022 | |
| Pfizer INC. | $179.81 | 2019-2022 | |
| Novo Nordisk INC | $179.26 | 2019-2022 | |
| Evofem Biosciences, INC. | $137.20 | 2021-2022 | |
| Roche Diagnostics Corporation | $111.86 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.74 | 2019-2021 | |
| Meditrina | $97.41 | 2022 | |
| Currax Pharmaceuticals LLC | $93.43 | 2019-2021 | |
| Astellas Pharma US INC | $92.00 | 2019-2022 | |
| Davol INC. | $87.86 | 2021 | |
| Hologic Sales and Service, LLC | $82.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.75 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $62.72 | 2019-2020 | |
| Coopersurgical, INC. | $56.12 | 2020-2021 | |
| Exeltis, USA INC. | $53.21 | 2019-2021 | |
| Myovant Sciences INC. | $49.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.98 | 2019-2022 | |
| Daiichi Sankyo INC. | $33.22 | 2019 | |
| Boston Scientific Corporation | $32.94 | 2022 | |
| Biom'Up France Sas | $32.35 | 2021 | |
| Organon LLC | $32.18 | 2022-2023 | Nexplanon |
| Vivus LLC | $29.41 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $27.87 | 2019 | |
| Millicent US INC | $25.59 | 2019 | |
| Duchesnay USA Incorporated | $17.32 | 2019 | |
| Sanofi Pasteur INC. | $15.87 | 2019 | |
| Bausch Health US, LLC | $15.62 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.08 | 2019 | |
| Covidien LP | $14.66 | 2019 | |
| Shire North American Group INC | $13.40 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Roh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.